Gene therapy directed specifically to the vascular wall, particularly to angiogenic endothelial cells is a prerequisite in vascular disease treatment. Angiogenesis is a major feature in many pathological conditions including wound healing, solid tumors, developing metastases, ischemic heart diseases and diabetic retinopathy. In the present study we developed a tissue-specific gene therapy to the angiogenic blood vessels of tumor metastasis using an adeno-based vector containing the murine preproendothelin-1 (PPE-1) promoter. Genes activated by the PPE-1 promoter were highly expressed in bovine aortic endothelial cells in vitro. Systemic injection of the adenoviral vectors AdPPE-1-
Introduction
Most solid tumors are angiogenesis-dependent, and thus anti-angiogenic therapy approach represents an attractive strategy for treatment of a wide range of tumors. 1 Moreover, because of the inherent genetic stability of resting and angiogenic vascular endothelial cells, they are less susceptible than the tumor cells to become drug resistant. 1 The vascular endothelium represents a potential target for gene therapy due to its large surface area, proximity to the circulation and its major role in regulating important biological processes in tumor angiogenesis. 2 Gene therapy is an emerging modality for treating inherited and acquired human diseases. However, there are a number of obstacles limiting successful gene therapy including: duration of expression, induction of the immune response, cytotoxicity of the vectors and tissue specificity determined by the target cell or tissue. [3] [4] [5] [6] [7] Thus, developing a system to direct gene expression to endothelial cells that will be expressed specifically in the angiogenic vessels of solid tumors and metastasis, will enable us to treat these conditions efficiently.
The efficacies of gene transfer into the vessel wall have been demonstrated by using both cationic liposomes and adenoviral vectors. Nabel et al [8] [9] [10] have successfully transfected human growth factors (platelet derived growth luciferase and AdCMV-luciferase to normal C57BL/6 mice, resulted in higher activity of PPE-1 promoter compared with CMV promoter in the aorta and vascularized tissues such as heart, kidney, lung and pancreas. Systemic administration of the adenoviral vector, in mice bearing Lewis lung carcinoma, resulted in high and specific activity of PPE-1 in the new vasculature of primary tumors and lung metastasis. Cellular distribution of the delivered gene revealed highest expression of GFP in angiogenic endothelial cells of the metastasis. We expect that this approach of 'vascular-directed' gene therapy will be applicable to both vascular diseases and cancer. Gene Therapy (2001) 8, 819-827.
factor-BB (PDGF-BB), fibroblast growth factor-1 (FGF-1) and transforming growth factor ␤1 (TGF␤1) cDNAs into porcine iliofemoral arteries by using cationic lyposomes. [8] [9] [10] Lemarchand et al 11, 12 examined the feasibility and stability of gene expression in the ligated region of sheep carotid arteries and veins. One of the limitations of these studies was the local application, which is invasive and clinically impractical especially in tumor metastasis. Several studies have used retroviruses, adeno-associated, and adenoviral vectors. 4, 13 However, in most studies no endothelial-specific promoters have been used. Therefore, the transgene was delivered mainly by invasive techniques, and expressed mainly in non-vasculature organs, such as the liver.
In order to target a therapeutic gene expression specifically to vascular endothelial cells, one should use either tissue-targeting vectors or tissue-specific promoters. In vitro and in vivo experimental models showed higher endothelial gene expression by using the endothelial cells specific promoters, such as von-Willebrand (vWF) factor, 14 intracellular adhesion molecule 2 (ICAM-2), 15 tie 2, 16 vascular endothelial growth factor (VEGF) receptor (KDR) or E-selectin. 17 However, none of these promoters directed the gene expression to tumor angiogenic endothelial cells. We have shown that the PPE-1 promoter can direct gene expression specifically to the vascular wall in transgenic mice. 18 The murine PPE-1 promoter highly specific activation in vascular endothelial cells is due to the presence of the cis element ETC/D/E in the promoter. This element is missing in the human ET-1 promoter. 19 Endothelins are a family of peptides produced by vascular endothelium in response to injury, hypoxia, ischemia, inflammatory mediators, thrombin, transforming growth factor beta, stretch and shear stress. They are also mitogens for endothelial cells, fibroblasts and vascular smooth muscle cells. [20] [21] [22] Endothelins trigger the production of angiogenic factors in response to hypoxia and may have a role in tumor neovascularization. [23] [24] [25] Since the endothelin is produced and activates mitogenic signaling in several human cancer cells, and interact with VEGF, its promoter can be used to direct genes specifically into the vascular bed in this process. [24] [25] [26] [27] Therefore, in the current work we have used an adenobased vector containing the murine preproendothelin-1 (ET-1) promoter to direct gene expression specifically to endothelial cells in normal and angiogenic vessels.
Results
The efficiency and specificity of Ad5PPE-1Luc in vitro The efficacy of Ad5PPE-1Luc to deliver the reporter gene luciferase into cells and its specific activity in endothelial cells were first tested in vitro. Ad5CMVLuc was used as a non-tissue-specific control virus. Under the control of the PPE-1 promoter luciferase activity was 60 times higher in endothelial cell lines (human umbilical vein endothelial cells (HUVEC) and bovine aortic endothelial cells (BAEC)) compared with its activity in non-endothelial cells, rat insulinoma (RIN) (Figure 1a ). Luciferase activities in the endothelial cell lines under the control of the PPE-1 promoter was 15 to 30 times higher than under the control of the CMV promoter at the same infection conditions (MOI, 1). On the other hand, luciferase expression in RIN cells was 100 times higher under the control of the CMV promoter ( Figure 1a ). The efficacy of the Ad5PPE-1Luc to transduce foreign genes into human cell lines was also tested. Under the control of the murine PPE-1 promoter the luciferase activity was higher in endothelial cells (BAEC) compared with its activity in the non-endothelial cells (HeLa, HepG2 and normal skin fibroblasts, NSF) (Figure 1b) . On the other hand, luciferase expression in non-endothelial cells was higher under the control of CMV promoter (Figure 1b) .
In freshly prepared HUVEC cells the luciferase expression under the control of PPE-1 promoter was 120 930 ± 2516 which is 187 times higher than the expression under the CMV promoter control (648 ± 246).
The PPE-1 promoter activity in proliferating cells was compared with its activity in quiescent BAEC cells (Figure 2 ). The PPE-1 promoter was four times more activated in proliferating BAEC than in quiescent cells, and 25 times more activated in proliferating BAEC than the CMV promoter.
The efficacy of the adenoviral vectors to transduce foreign genes into Lewis lung carcinoma (LLC) cells was also tested. The results indicate that both adenoviral vectors are able to transduce the luciferase gene to these cells (Table 1) . Nevertheless, luciferase activity directed by the PPE-1 promoter was much lower in the LLC cells than the activity detected in endothelial cells, 50 versus 1000-2500 light units/g protein, respectively. The efficiency, specificity and stability of Ad5PPE-1Luc in vivo The efficiency of Ad5PPE-1Luc to deliver the reporter gene luciferase, its specific activity and stability in vascularized and non-vascularized tissues, were tested in C57BL/6 mice. As expected, in Ad5CMVLuc-treated mice, most of the luciferase activity (60-80% of the total body expression) was found in the liver. On the other hand, luciferase activity controlled by the PPE-1 promoter was lower in the liver (37-54% of the total body expression). The PPE-1-derived expression was much higher in the aorta (23-33% of the total body expression 5 and 14 days after injection, respectively), compared with Ad5CMVLuc-treated mice (up to 1.8% of total body expression) ( Table 2 ).
The highest luciferase activity was detected in the aortas of Ad5PPE-1Luc-injected mice 5 and 14 days after injection (Table 2) , while low luciferase activity was detected 30 days after injection and no activity was meas-
Figure 2 Luciferase activity in proliferating and quiescent bovine aortic endothelial cells (BAEC) transduced with Ad5PPE-1Luc (open bars) and Ad5CMVLuc (black bars). The cells were transduced for 48 h: (a) 72 h after serum deprivation; (b) in normal media (10% FCS). Luciferase activity is expressed as light unit/g protein.

Table 1
In vitro transduction of Lewis lung carcinoma cell line (D122-96) with Ad5PPE-1Luc and Ad5CMVLuc ured 90 days after injection (data not shown). In Ad5CM-VLuc-treated mice, the highest liver activity was detected 5 days after injection following with significant decrease (P Ͻ 0.05) 14 days after injection ( Figure 3 ).
Cellular localization of gene delivered by Ad5PPE-1 in vivo
To localize the gene expressed by PPE-1 in vivo, green fluorescent protein (GFP) delivered by the adenoviral 1.6 ± 1.1 22.6 ± 6.0 1.8 ± 0.5 Heart 0.64 ± 0.5 1.5 ± 0.8 2.7 ± 0.8 1.6 ± 0.7 Liver 54.7 ± 6.3 78.7 ± 8.3 37.9 ± 6.3 59.3 ± 11.7 Muscle 0.9 ± 0.5 0.7 ± 0.4 2.5 ± 0.9 1.9 ± 0.7 Kidney 0.17 ± 0.08 0.9 ± 0.8
12.5 ± 6.4 22.2 ± 6.1 28.5 ± 10.3 Spleen 4.7 ± 4.2 1.9 ± 1.2 3.7 ± 0.8 2.3 ± 0.7 10 10 pfu/ml Ad5PPE-1Luc or Ad5CMVLuc were injected into the tail vein of C57BL/6 mice. Luciferase activity in tissues was measured 5 and 14 days after injection. The results are expressed as the percentage expression from the total expression in each mouse. In other organs not mentioned in the Table there was minimal or undetectable expression.
Gene Therapy vector Ad5PPE-1GFP was used. Ad5CMVGFP was used as a non-endothelial-cell-specific control. Five days after intravenous injection, the mice were killed and their tissues were analyzed by a fluorescent microscopy. In the mice injected with Ad5CMVGFP vector, most of the expression was detected in the hepatocytes, and no expression was detected in the endothelial cell in the liver (Figure 4a ). On the other hand, Ad5PPE-1GFP-injected mice, showed no expression in hepatocytes, but significant expression in endothelial cells in the blood vessels of the liver (Figure 4b) . Similar results were obtained in other tissues where practically all the PPE-1-derived expression was detected in the endothelium, while none of the CMV-derived expression was detected in these tissues.
Gene expression in tumor neovascularization
The efficacy of the adenoviral vector to deliver genes to proliferating angiogenic endothelial cells in vivo was tested in LLC angiogenesis model. As previously described by O'Reilly et al 28 high vascularization was found in lung metastasis and low vascularization in the primary tumor. Systemic injection of Ad5CMVLuc in both primary and metastatic tumor models resulted in minimal expression in the tumor itself or in the metastatic lung. This level of expression was similar to the minimal expression of luciferase directed by CMV in naive normal lungs ( Figure 5 , black bars). On the other hand, under the control of PPE-1 promoter ( Figure 5 , open bars), the high vascularization of lung metastasis was associated with higher luciferase activity, which was about 200 times higher than the luciferase activity in the non-vascularized primary tumor and the naive lungs.
The luciferase expression in non-metastatic tissues such as the liver, kidney, heart and pancreas was minimal. The expression level in the aorta was about 30% of the levels in the metastatic lungs.
Ad5PPE-1GFP-injected mice showed high levels of specific expression of GFP in the blood vessels of the primary tumor (Figure 6 ), no expression was detected in the tumor cells themselves. In the metastatic lung, high levels of GFP expression were detected in both big arteries and small angiogenic vessels in the metastasis (Figure 7a ). No expression was detected in the normal lung tissue. The endothelial cell localization was demonstrated by co- localization of the GFP expression (Figure 7a ) and the CD31 antibody immunostaining (Figure 7b) . In striking contrast, in Ad5CMVGFP-injected mice, no GFP activity was detectable in both the primary tumor and lung metastasis.
Intratumor injection of Ad5CMVLuc in a primary subcutaneous tumor model resulted in high luciferase expression in the tumor tissue and moderately high levels of expression in the liver (10% of the amount expression in the tumor). No expression was detected in the metastatic lungs. On the other hand, luciferase expression under the control of the PPE-1 promoter resulted in similar luciferase levels of expression in the primary tumor and the metastatic lungs and no expression was detected in the liver.
Discussion
In the present study, we developed an adenoviral vector containing the endothelial cell-specific PPE-1 promoter. Reporter genes delivered by the vector were specifically expressed in vascularized tissues of normal C57BL/6 mice and highly expressed in endothelial cells of tumor angiogenesis. Hence, the adenoviral vector has the potential to target therapeutic genes to vascular endothelial cells in angiogenesis.
The in vitro studies showed that the developed viral vector, Ad5PPE-1Luc, is able to transduce the luciferase gene specifically to endothelial cells, and that it is an endothelial specific promoter across different species.
Our results suggest that the PPE-1 promoter is more activated in proliferating endothelial cells compared with quiescent endothelial cells. This effect might be important in systemic gene therapy for angiogenesis and explain the specificity we obtained in the metastatic lung model as discussed later.
Other EC-specific promoters have been previously used to express gene specifically in EC both in vitro and in vivo. These promoters include: von-Willebrand (vWF) factor that showed poor transfection efficiency, 14 intracellular adhesion molecule 2 (ICAM-2), that directed strong and specific expression in the EC of transgenic mice, 15 and the murine tie-2 promoter fragment that lacked EC specificity in vitro, but showed high and specific activity in transgenic mice. 16 However, these EC-spe-
Figure 5 Luciferase activity in normal lung, lung metastasis and primary tumor of Lewis lung carcinoma-induced mice. Lewis lung carcinoma was induced by D122-96 cell injection to the backs in the primary tumor model and to the foot pad in the metastatic model. Luciferase activity was measured 5 days post-systemic injection of Ad5PPE-1Luc (n = 9) (open bars) or Ad5CMVLuc (n = 12) (black bars) as described in Materials and methods. Activity is expressed as light units/mg protein.
cific promoters have not been used in gene delivery models such as retrovirus and adenovirus-based vectors. High efficiency of the human preproendothelin-1 (PPE-1), delivered by retroviral vector, was obtained in EC in vitro, but it has not been assayed in animal models. 29 We have used the murine PPE-1 promoter since the murine promoter is specifically and highly activated in vascular endothelial cells, due to the presence of the cis element ETC/D/E in the promoter, that is missing in the human ET-1 promoter. 19 Moreover, transgenic mice expressing the luciferase reporter gene controlled by the PPE-1 promoter showed a vascular tissue-specific distribution of the reporter gene luciferase. 18 Indeed, high levels of gene expression were detected in the vasculature of the naive C57BL/6 mice injected with the PPE-1 virus, where no such expression was detected in the CMV-injected mice. Moreover, in the CMV-injected mice, 79% of the total body expression was detected in the liver hepatocytes where lower expression was detected in the PPE-1 injected mice, 55% of the total body expression. This activity was limited to the endothelial cells of the liver vein and sinuses. Similar luciferase biodistribution was observed in tissues of naive BALB/C mice injected with Ad5PPE-1Luc or Ad5CMVLuc (data not shown). Both in vitro assays in human cell lines and the activity in vivo in BALB/C mice indicate that the murine PPE-1 promoter is active and endothelial restricted across species.
Fechner et al 30 found that although the levels of CAR and/or that of ␣ v -integrin-mRNA expression in different tissues are determinants for vector targeting, other factors such as anatomical barriers play a major role in vector targeting after systemic injection. The vascular endothelium that in many organs (muscle, lung, brain and heart) is very tight, can reduce or even completely block the passage of adenoviral vectors. In the liver, spleen and bone marrow there are pores up to 100 nm in diameter, Gene Therapy a b
Figure 6 Green fluorescent protein (GFP) gene expression in primary tumor of Ad5PPE-1GFP-injected animals. Lewis lung carcinoma was induced by D122-96 cell injection in the back as described in Materials and methods. Tissues were collected and analyzed for GFP expression 5 days after Ad5PPE-1GFP injection, (a) phase microscopy and (b) GFP fluorescence microscopy.
wide-meshed basal membrane, and sparse connective tissue, so that adenoviral vector, which are smaller in size can gain easy access to these organs, provided that they also have the necessary receptors. Thus, the high efficiently transfected liver (up to 90% of the viral load) is affected from both the large endothelial pores and the levels of expression of the adenovirus receptors.
One obstacle in adenovirus-based gene therapy is its short duration of gene expression, 3, [5] [6] [7] often limited to several days or a few weeks. This short duration is caused by the immune response and the fact that viral promoters are usually used. Our results showed that luciferase peak expression in the aorta had lasted for up to 14 days after injection. On the other hand, luciferase activity under the control of CMV promoter showed the highest liver activity 5 days after injection followed by a sharp decrease in activity at 14 days. We assume that using a mammalian promoter and the expression in EC extend the duration of our transgene expression.
Gene Therapy a b
Figure 7 Green fluorescent protein (GFP) gene expression and CD31 staining in lung metastasis of Ad5PPE-1GFP-injected animals. Lewis lung carcinoma was induced by D122-96 cell injection in the foot pads as described in Materials and methods. Lungs were collected and analyzed for (a) GFP expression 5 days after Ad5PPE-1GFP injection, showing expression in both big and small intra-metastatic angiogenic vessels. (b) CD31 staining of Lewis lung carcinoma, lung metastasis, showing the small intrametastatic angiogenic vessels.
Regional intratumor administration of the viral vectors showed that although luciferase gene expression controlled by the PPE-1 promoter was relatively low in the primary tumor, similar levels of expression were detected in metastatic lungs of the same animals. Since in LLC model the primary tumor is low angiogenic and the lung metastases is highly angiogenic, we assume that the higher levels of expression in the lung metastases, is due to specific activity of the PPE-1 promoter in angiogenic blood vessels of the lung micrometastasis.
Systemic administration of Ad5PPE-1Luc in the tumor models, resulted in high luciferase activity in primary tumor and lung metastasis in comparison to Ad5CM-VLuc. Interestingly, the activity under CMV promoter was almost undetectable in both normal and metastasis lungs. On the other hand, the highest activity levels were found in lung metastasis of mice injected with the PPE-1 virus. This activity was about 200 times higher than the activity in the normal lungs despite the fact that lungs are highly vascularized. In vitro analysis of the luciferase viruses showed that the activity of both viruses is low and similar in the LLC cell lines. The PPE-1-derived activity in these cells was 30-40 times lower than in EC. GFP expression controlled by the PPE-1 promoter demonstrated that the reporter genes were specifically expressed in EC in the new blood vessels of the primary tumor and in positive CD31 cells in lung metastasis, but not in the tumor cells and other tissues. Thus, tumor cell expression could not be the reason for the higher levels of expression in primary and metastatic tumor directed by the PPE-1 promoter. Rather, a specific expression in the angiogenic vessels cause the high levels of this expression in both tumor models.
It is possible that transducing the angiogenic active endothelial cells is easier than transducing normal quiescent endothelial cells, due to their high number of ␣ v ␤ 3 integrin on the angiogenic blood vessels surface. [31] [32] [33] Another explanation might be that PPE-1 promoter is highly activated in angiogenic tumor cells. Indeed, endothelin-1 is activated and stimulates tumor growth 26, 27 and angiogenesis by interaction with VEGF, 23, 24 PDGF and other factors. 34, 35 Since ET-1 expression is up-regulated by hypoxia and other factors in the tumor milieu, the highest PPE-1-derived reporter gene activity in metastasis in our experiments might be due to the same transcription factors, such as hypoxia inducible factor (HIF) that activate ET-1 expression in tumor vasculature. Thus, it was not surprising that the reporter genes are up-regulated in the tumor endothelial cells when directed by the PPE-1 promoter.
Our results suggest that a possible application of PPE-1-based adenoviral vector will be in the gene therapy of cancer. Since angiogenesis is required for tumor growth and metastasis, tumor can be 'starved to death' and metastasis can be prevented by EC-directed gene therapy. 1, 32, 36 Holmgren et al 37 and Boehm et al 38 demonstrated that systemic administration of human angiostatin potentially inhibits the growth of several human and murine primary carcinoma and promote long-term dormancy of metastasis in Lewis lung carcinoma (LLC) mouse model. Tanaka et al 13 subsequently developed angiostatin-expressing adenoviral vectors controlled by the nonspecific promoter CMV. Injection of the vector directly into pre-established glioblastomas tumors resulted in tumor regression and prolonged the mouse survival. The disadvantage of this approach is the local delivery which is not likely to be clinically useful. Systemic delivery of adenoviral vector containing the soluble endothelium-specific receptor tyrosine kinase receptor, Tie 2, controlled by the CMV promoter, inhibited metastasis in mice. 39 Yet, using EC-specific promoter can improve this approach. The PPE-1 promoter with its induction in angiogenesis is a good candidate.
The lower levels of gene expression in the liver and other tissues enable this system to reduce toxicity caused by the specific genes to be used for tumors in gene therapy. Thus, the newly developed Ad5PPE-1 delivery system can be potentially used to direct genes specifically into the endothelium in EC-involved processes such as wound healing, atherosclerosis, ischemia and tumor angiogenesis. The effectiveness of the delivery system should be further investigated by using therapeutic genes such as the herpes simplex virus thymidine kinase (HSVtk) or pro-apoptotic genes for reducing tumor angiogenesis, or pro-angiogenic genes for inducing angiogenesis in ischemic heart diseases or in wound healing.
Materials and methods
Cell culture
Lewis lung carcinoma (D122-96) (kindly provided by Professor L Eisenbach, Weizmann Institute of Science Rehovot, Israel), human embryonic kidney (293) and HeLa cells were grown in 4.5 g/l DMEM, supplemented with 10% fetal calf serum (FCS), 50 U/ml penicillin, 50 g/ml streptomycin and 2 mm glutamine (Biological Industries, Beit-Haemek, Israel). Bovine aortic endothelial cells (BAEC) (kindly provided by Professor N Savion, Goldshlager Institute, Sheba Medical Center, Tel-Hashomer, Israel), normal skin fibroblasts (NSF), HepG2 and human umbilical endothelial cells (HUVEC-304) (ATCC, USA) were grown in 1.0 g/l DMEM (Biological Industries), supplemented with 5% FCS, 50 U/ml penicillin, 50 g/ml streptomycin and 2 mm glutamine. The BAEC cells were supplemented with complete fibroblast growth factor (Sigma, St Louis, MO, USA). RINr1046-38 (RIN-38) were grown in 199 Earle's salt (5.5 mm glucose) medium supplemented with 5% FCS (Biological Industries), 50 U penicillin/ml, 50 g streptomycin/ml and 2 mm glutamine.
Proliferating and quiescent cells
In order to compare the PPE-1 promoter activity in proliferating and quiescent BAEC, the cells were divided into two groups: (1) proliferating cells, growing and infecting in 10% FCS media; (2) quiescent cells, growing and infected in serum-free medium started 72 h before the transduction.
All cells were grown in humidified incubator, 5% CO 2 , 37°C.
Preparation of recombinant replication-deficient adenoviruses All recombinant replication-deficient adenoviruses (type 5) were constructed according to the procedure reported by Becker et al. 40 The murine preproendothelin-1 (PPE-1) promoter located upstream to the luciferase gene and the SV40 polyA site, was ligated into the BamHI restriction site of pPAC.plpA (promoterless). The GFP gene was ligated to the PPE-1 promoter into the NotI restriction site. The replication-deficient recombinant adenoviruses termed Ad5PPE-1Luc or Ad5PPE-1GFP were prepared by co-transfection of pPACPPE-1Luc or Ad5PPE-1GFP with adenovirus plasmid pJM17 and harvested the recombinant virions as previously described. 41 Viruses were prepared for large-scale production according to the procedure described previously. 41 The viral stocks were stored at 4°C at concentration of 10 9 -10 12 plaque-forming units/ml (pfu/ml). The virus Ad5CMV-Luc (kindly provided by R Gerard, UTSw Dallas, TX, USA) and Ad5CMV-GFP (Quantum Biotechnologies, Carlsbad, CA, USA) containing the cytomegalovirus (CMV) immediate-early promoter were prepared for large scale preparation as described for the PPE-1 viral vectors and were used as non-tissue-specific control.
Luciferase activity in cells and tissues Luciferase activity in vitro and in vivo was determined as previously described. 18 Gene Therapy
GFP activity in tissues
To test the cellular distribution of the delivered gene in vivo, tissues were fixed in freshly made 4% paraformaldehyde in 0.1 m phosphate buffer for 6 h at 4°C, soaked overnight in 30% sucrose at 4°C and freezed in OCT compound (Sakura, CA, USA). The tissue blocks were sliced at 10 m thickness and observed directly under fluorescence microscopy (FITC filter).
In vitro experiment, DNA transduction Cells were plated in 16 mm dishes 24 h before transduction. DNA transduction of BAEC (bovine aortic endothelial cells), HUVEC (human umbilical vein endothelial cells), LLC (Lewis lung carcinoma) and RIN (rat insulinoma), HepG2, HeLa and normal skin fibroblasts (NSF) cells were performed by incubation with 1, 5 and 10 multiplicity of infection (MOI) of Ad5PPE-1Luc. for 4 h in a total volume of 500 l growing media, following by incubation with the growing media in a total volume of 2 ml for 48 h. Ad5CMVLuc was used as a non-tissuespecific control.
Animals
Male, 3-month-old C57BL/6 mice (Harlan Farms, Jerusalem, Israel), were used. All animal procedures were approved by the Animal Care and Use Committee of Sheba Medical Center, Tel-Hashomer.
Tissue gene expression in normal mice
To assay the efficiency and tissue specificity, Ad5PPE1-Luc or Ad5CMVLuc (as non-tissue-specific control), 10 10 pfu/ml in 100 l physiological saline, were injected into the tail vein of normal 3-month-old male C57BL/6 mice. Luciferase activity was assayed 1, 5, 14, 30 and 90 days after injection. To localize the cellular distribution of the reporter genes expression, Ad5PPE-1GFP or Ad5CMVGFP (10 10 pfu/ml in 100 l physiological saline) were injected into the tail vein of normal 3-month-old, male C57BL/6 mice. GFP expression was detected 5 days after injection. All mice appeared healthy and no toxicity or inflammation was noted in the liver or other tissue.
Tumor implantation
Lewis lung carcinoma cells (LLC) were harvested with trypsin/EDTA, washed three times with PBS and counted with 0.1% trypan blue (Biological Industries) to assess their viability. In order to test the PPE-1 promoter activity in tumor angiogenesis, two different tumor models were used in C57BL/6 mice. In the primary tumor model, the cells (1 × 10 6 cells/ml in 100 l physiological saline) were subcutaneously injected to the mice backs (n = 17). Twenty-one days after injection Ad5PPE-1Luc, Ad5PPE-1GFP, Ad5CMVLuc, or Ad5CMVGFP (10 10 pfu/ml) were injected into the tumor tissue (IT) or intravenously and their activity were detected as described above. In the metastatic tumor model, the cells (5 × 10 5 cells/ml in 50 l physiological saline) were injected to the mice foot pad (n = 12). When the tumor tissue reach the size of 0.7 mm diameter, the foot pad (with the primary tumor) was resected under anesthetic and sterile conditions. Fourteen days after surgery the viruses (Ad5PPE-1Luc., Ad5PPE-1GFP, Ad5CMVLuc or Ad5CMVGFP) were injected into the mouse tail vein.
In all tumor experimental models mice were killed 5 days after viral injection, their tissues were excised and tested for luciferase or GFP activities.
Histological examination
In order to evaluate the extent of the angiogenic process in the tumor and metastasis, the tissues were sliced to 5 m and stained with hematoxilin and eosine (H&E). Anti-CD31 (rat anti-mouse CD31 monoclonal Ab, Pharmingen, NJ, USA) were used for analyses of neovascularization in the tumor models according to the procedures previously described. 42 
Statistical analysis
Data are shown as mean ± s.e. Analysis between groups for statistically significant differences was performed with the use of t-test ANOVA, or the Mann-Whitney rank test.
